Latest Headlines

Latest Headlines

WPP Group buys CMI healthcare and pharma media agency

Adding to its healthcare heft, WPP Group bought CMI, a healthcare media agency that counts 10 of the largest 20 pharma advertisers among its clients.

Affymetrix spurns bid by former execs in favor of $1.3B offer from Thermo Fisher

Affymetrix, a maker of advanced genetic analysis technology, has rejected an unsolicited bid by former executives in favor of the $1.3 billion offer it received from Thermo Fisher Scientific earlier this year.

Bristol-Myers bags biotech upstart Padlock in $600M autoimmune deal

Bristol-Myers Squibb has struck a $600 million deal to buy out the biotech startup Padlock Therapeutics and its autoimmune R&D; platform.

Precision for Medicine broadens cancer trial offering with ACT Oncology buy

Precision for Medicine has signed a deal to acquire ACT Oncology--a leading CRO in the field of cancer studies--as together the new company looks to become a leading light in the personalized cancer clinical trial space.  

UPDATED: Thermo Fisher CEO urges Affymetrix shareholders to sign off on $1.3B deal despite rival bid

Thermo Fisher Scientific CEO Marc Casper has a message to Affymetrix stockholders about its planned $1.3 billion buyout of gene editing firm: Make the right decision.

Thermo Fisher forges ahead with $1.3B Affymetrix deal after rival bid rejected

Just when Thermo Fisher Scientific thought it had reached the finish line of its previously announced $1.3 billion deal for gene editing firm Affymetrix, things got complicated. A shell company recently put up an 11th-hour takeover bid meant to derail the sale. But at least for now, Affymetrix isn't buying it.

Following on from GSK deal, WNS adds data analytics capabilities in $17.5M buyout

WNS has moved to acquire Value Edge Research Services for $17.5 million. The deal, which comes shortly after WNS extended its contract with GlaxoSmithKline, will add biopharma-focused data analytics capabilities to the offering of the business process management player.

What's next for Gilead in oncology?

As competition for its hepatitis C drugs intensifies, Gilead Sciences has been working to build up in other therapeutic areas, especially cancer. And while a painful clinical failure for the blockbuster hopeful Zydelig and the high-profile departure of oncology head Philippe Bishop have hamstrung those efforts, Gilead is bullish about its future in the field.

Vectura lands $621M merger deal with SkyePharma

Vectura has secured a friendly merger with SkyePharma that will see its chief executive depart as the combined company looks to a new and expanded future.

Teva hits roadblock in Allergan generics buy, potentially delaying 'Pfizergan' close

Investors' worries over the closing of Teva's $40.5 billion deal for Allergan's generics unit are being realized, with the Israeli drugmaker Tuesday reporting that a delay is on the way. And looking ahead, that may also spell a delay for Pfizer's pickup of the rest of Allergan, too.